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Naronapride
(6-[(3S,4R)-4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methoxypiperidin-1-yl]-hexanoic acid 1-aza-bicyclo[2,2,2]oct-(R)-3-yl ester dihydrochloride ) is an orally-active serotonin 5-HT 4 receptor partial agonist being developed for the treatment of gastrointestinal motility disorders including functional dyspepsia, gastroesophageal reflux disease (GERD), and chronic idiopathic constipation (CIC; Manabe et al., 2010; Camilleri & Bharucha, 2010; Camilleri et al, 2009) . Unlike other members of its class (e.g. tegaserod
[USFDA Center for Drug Evaluation and Research, 2002; Camilleri, 2001] and cisapride [Mohammad et al, 1997; Pau et al, 2005; Suffredini et al, 2010] ), naronapride has relevant affinity for only the 5-HT 4 receptor subtype (K i = 1.4 nM), negligible affinity for K v 11.1 channels (hERG; K i = 24,500 nM; Palme et al, 2004 ) and no effect on cardiac repolarization (Palme et al, 2005; Milner et al., 2010) . When tested in wide-spectrum in vitro screening assays using radioligand binding techniques, naronapride (≥10 µM) was found to significantly interact with Although the clinical implications of this interaction are not known at this time, observed dose-related increases in prolactin levels noted in rats after single dose administration of naronapride suggest a relationship to D 2 receptor antagonism (unpublished observations).
Like other high-affinity 5-HT 4 receptor agonists (e.g. cisapride, tegaserod, prucalopride), naronapride is a potent enterokinetic agent and, in animal models, has been shown to increase upper and lower-bowel motility when it is administered orally, systemically, or intracolonically (ARYX Therapeutics, unpublished findings; Balemba & Mawe, 2009) . Results of clinical studies
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6 carried out to date indicate that oral naronapride increases gastric and colonic motility in healthy volunteers (Camilleri et al., 2007) , decreases gastric acid exposure to the esophagus and increases symptom-free days of nocturnal heartburn and dyspeptic symptoms in patients with symptomatic GERD (ARYx Therapeutics, unpublished results). In a recent Phase 2 study in CIC patients, naronapride increased spontaneous bowel movements and decreased the time to first bowel movement . Naronapride is currently in late-stage clinical development for the treatment of CIC.
The objective of this investigation was to determine the absorption, metabolism, and excretion of naronapride in healthy male subjects given a single oral dose of 14 C-labeled compound (Fig 1) . To elucidate metabolic and excretory pathways, major and minor metabolites were identified and quantified in plasma, urine, and feces. The pharmacokinetics of naronapride and its metabolites after a single oral naronapride dose were also determined. To investigate the role of CYP450 monooxygenases in naronapride biotransformation, the metabolic profile of naronapride in human liver microsomes was determined in the presence and absence of an nicotinamide adenine dinucleotide phosphate (NADPH)-generating system.
The metabolic profile of naronapride was also determined using cryopreserved human hepatocytes to assess Phase I and Phase II metabolic activity. 
METHODS
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7 was expected to be minimal (i.e. less than 5% of the allowable amount) at this dose based on the dosimetry analysis of the results from a quantitative whole-body autoradiography tissue distribution study in rats. Biological samples were collected for up to 552 hrs after dosing.
Blood and plasma were collected predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, 120 , and 144 hrs postdose into vacutainers containing 1% ethanolic paraoxon to prevent ex vivo hydrolysis. Urine was collected predose, and 0-2, 2-4, 4-8, 8-12, 12-24, 24-36, 36-48 hrs postdose and at 24 hr intervals thereafter, as applicable. Feces was collected predose and at 24 hr intervals as applicable. Blood, collection and/or analysis of samples was discontinued when the concentration of radioactivity in blood, plasma, urine, and feces were equal to or less than 2-times the matrix background activity or after ≥ 90% of the dose radioactivity was recovered in urine and feces. Samples were analyzed for total 14 C radioactivity. Metabolite identification and profiling was accomplished using HPLC/MS/RAD methods. Naronapride and its major metabolites were measured in selected plasma samples using LC/MS.
Pharmacokinetic analyses of the individual blood and plasma radioactivity and plasma concentrations of naronapride and its major metabolites were conducted using a noncompartmental approach with the validated computer program WinNonlin (ver. 5.1.1). For blood and plasma radioactivity, the pharmacokinetic parameters determined included C max , t max , AUC and blood to plasma radioactivity AUC ratio. For plasma naronapride and its major metabolites, the pharmacokinetic parameters determined were C max , t max , AUC ∞ , t 1/2,z , Cl o , CL r , V z /F and metabolic AUC ratios. For urine and feces radioactivity, including naronapride and major metabolites, the pharmacokinetic parameters were the cumulative recovery of radioactivity and analytes.
This study was performed in accordance with local regulations and the principles of the HPLC Radio-analysis and HPLC/MS System. Naronapride and its metabolites were separated using reverse phase liquid chromatography and detected by a radio flow-through detector and linear trap quadrupole mass spectrometer simultaneously. The system for metabolite profiling and identification consisted of a Finnigan autosampler, a Surveyor HPLC pump, an LTQ mass spectrometer, and a β -RAM Model 3 radio flow-through detector (Perkin Elmer, Waltham, MA). The mass spectrometer was controlled by Xcalibur (ThermoFisher
9 Scientific, Pittsburg, PA) software, and the radio flow-through detector was controlled by Laura Lite 3 (LabLogic Systems, Brandon, FL). The HPLC eluent was split between the radio flowthrough detector and MS with a ratio of 3 to 1. HPLC separation was carried out using a Phenomenex Synergi Max RP, 250 X 4.6 mm, 5 µm column. The mobile phase was A: 0.1% formic acid in 5 mM ammonium formate, B: 0.1% formic acid in MeOH; %B was cycled from 10% to 90% to 10% over 35 minutes at a flow rate of 800 µL/minute. Mass spectrometry conditions were as follows: sheath gas: 50 unit, auxiliary gas: 20 unit, sweep gas: 10 unit, ion Radio-analysis. The HPLC/ARC system was used for radio-quantification of all urine and fecal samples and of plasma samples with radioactivity exceeding 500 dpm/mL. HPLC fraction collection followed by counting with TopCount™ was used for radio-quantification of plasma samples with radioactivity between 200-500 dpm/mL. from the mean value, the sample was homogenized again and then reanalyzed (sample size permitting). This specification was met for all sample aliquots that had radioactivity greater than 100 dpm. Scintillation counting data were automatically corrected for counting efficiency using the external standardization technique and an instrument-stored quench curve generated from a series of sealed quenched standards.
Extraction Recovery of Fecal Samples. Extraction recovery of fecal samples was determined in 24 hr and 72 hr fecal homogenate samples (approximately 2 g each) from one subject.
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Samples were thawed, and triplicate aliquots (approximately 0.4 g each) were combusted. The combustion products were mixed with 10 mL of Carbosorb ® and 10 mL of Permafluor ® before counting using LSC. The radioactivity in the fecal homogenate was defined as 100%.
Approximately 2 g aliquots from the 24-hr and 72-hr samples were thawed and extracted with three volumes of methanol/acetonitrile/formic acid (25:75:0.5, v:v:v) . Each mixture was vortexed for 3 minutes, sonicated for 5 minutes, and centrifuged at 3000 rpm for 5 minutes. The supernatant was transferred to a clean tube, and the pellet was re-extracted two more times using 3 volumes of the MeOH:ACN:formic acid mixture. The radioactivity of the combined supernatant was determined by LSC, and the extraction recovery was calculated.
Extraction for Metabolite Identification and Profiling. Plasma, urine, and fecal samples were collected at multiple time points before and after [ 14 C]-naronapride dosing. All samples were stored at -70°C until analyzed. To ensure accurate radio-quantitation, samples with greater than 200 dpm/mL for plasma, 1000 dpm/mL for urine, and 2000 dpm/mL for fecal homogenate were used for quantitative analyses and metabolite identification. Plasma samples taken at 0.5, 1, 2, 4, and 8 hrs post-dose, all urine samples of all collection intervals out to 160
hr postdose, and all fecal samples collected at 24 hr intervals beginning 24 hrs postdose and ending 360 hrs postdose were processed for analysis.
Plasma samples from individual subjects were extracted by protein precipitation with acetonitrile and methanol. Plasma samples from each subject at each time point were aliquoted in triplicate (~1.0 mL aliquots), and 1.0 mL of 25% MeOH in H 2 O were added to each. After gentle mixing, three volumes (3.0 mL) of acetonitrile were added, vortex-mixed at a low speed and then centrifuged at 500 rpm for approximately 3 minutes. The supernatant was removed and placed in a clean, pre-weighed tube. Pellets were resuspended in 25% MeOH in H 2 O and re-extracted by addition of acetonitrile, followed by centrifugation. The supernatants were combined, dried down with a nitrogen stream and reconstituted using 1.0 mL of 100% MeOH.
The tubes were rinsed with the reconstitution solvent and were carefully pooled into one tube,
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12 dried down, and then reconstituted using 10% MeOH containing 1% formic acid. The final product was transferred to micro-centrifuge tubes and centrifuged at 15,000 rpm for 45 minutes to separate any residue, counted for radioactivity using LSC for extraction recovery and used for analysis. Each sample represented at least 85% of the total radioactivity for that sample.
Urine samples were centrifuged at 3000 rpm for 5 minutes, and the supernatant was used for analysis.
Fecal homogenate samples with radioactivity greater than 2000 dpm/gm from all subjects (approximately 5 g each) were extracted following the method used to determine extraction recovery as described above. For fecal samples with more than 10,000 dpm/mL, 2 g of sample were used. The supernatants from the extraction of each sample were evaporated to Urine and Feces HPLC Column Recovery. Samples (200 µL) were injected onto the HPLC system, and the eluent from 0 to 27 minutes was collected into a clean 50 mL centrifuge tube.
The total volume of eluant was recorded after collection. Triplicate aliquots (200 µL) of the HPLC eluant were counted using an LSC (Tri-Carb 2800TR, PerkinElmer, Waltham, MA). The average value of counting results was used to calculate the total radioactivity contained in the first collected eluant. Another 200 µL sample from the same subject and time point was injected into an HPLC system without the column installed, and the eluant from 0 to 10 minutes was collected into another clean 50 mL centrifuge tube. The total volume of eluant was recorded after collection. Triplicate aliquots (200 µL) of the HPLC eluant were counted using the LSC.
The average value of counting results was used to calculate the total radioactivity contained in the second collected eluant.
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Analysis and Metabolite Identification. HPLC/tandem mass spectroscopy coupled with radio flow-through detection was used for metabolite profiling and identification. The retention times of the metabolites were determined by the peaks on radio-chromatograms, and the molecular ions of the metabolites were determined on the full scan mass spectra corresponding to the retention times of metabolites on the radio-chromatograms. Tandem MS of the molecular ions was performed, and the structures of the metabolites were assigned based on interpretation of their mass spectra. The molecular weights of the major metabolites (representing ≥5% of the total radioactivity in a matrix compartment) were determined using LC/MS with various ionization modes and searching techniques (precursor ion scan and neutral loss scan).
Metabolite structures were confirmed using authentic standards of naronapride, ATI-7500, ATI-7400 and ATI-7100 (ARYx Therapeutics, Fremont, CA).
Quantification of Naronapride and Metabolites. Quantification of naronapride and its
metabolites at each collection period was based on the integration of peaks on their radiochromatograms. For plasma samples, the percent of total radioactivity in the sample for each peak at each time point was calculated, and was converted to ng equivalent (ng-Eq) of parent/mL. For urine and fecal samples, the percent of total radioactivity in the sample for each peak at each time period was calculated and was compared to ng-Eq of parent/g and to the percent of the administered dose. The limit of quantification for radioactivity was defined as the ratio of signal to noise (3:1) on the radiochromatogram. The limit of quantification was 100 dpm for the HPLC/ARC system and 12 dpm for TopCount™.
Due to the low radioactivity detected in the plasma samples and to provide better characterization of metabolite concentration-time profiles, LC/MS methods were developed and used for the measurement of naronapride and its major metabolites in addition to the simultaneous radio flow-through detection and mass spectroscopy method. The analysis was by gradient HPLC using either a Phenomenex Synergi Max RP 100A, 50 x 2 mm (for naronapride, ATI-7500, ATI-7400, and ATI-7100), 2.5 µm or Atlantis HILIC Silica, 30 x 2mm, 5
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14 µm column (for quinuclidinol). The mobile phase was A: 0.1% formic acid in 5 mM ammonium acetate, B: 0.1% formic acid in 90/10 acetonitrile/50 mM ammonium acetate (for naronapride and ATI-7500) or 0.1% formic acid in 100% MeOH (for ATI-7400 and ATI-7100) at flow rates of either 350 µL/min (naronapride and ATI-7500) or 300 µL/min (ATI-7400 and ATI-7100). The mobile phase for determination of quinuclidinol was A: 0.1% formic acid in 10 mM ammonium formate, B: 0.1% formic acid in 97.5/2.5 acetonitrile/10 mM ammonium formate at a flow rate of 300 µL/min. Authentic quinuclidinol, naronapride, ATI-7500, ATI-7400, and ATI-7100 were reference standards and deuterated naronapride, ATI-7500-d3, ATI-7400-d3, and ATI-7100-d3
were internal standards. Samples were analyzed on a Sciex API 5000 (Applied Biosystems)
triple quadrupole mass spectrometer equipped with an ESI source. transferred to a 50 mL conical tube containing 40 mL of pre-warmed HT medium. The hepatocytes were then centrifuged at 2000 rpm for 10 min, and the HT medium was removed.
The pellet was resuspended in Krebs-Henseleit (KH) buffer (10 mL), and the viability of the cells was determined by the Trypan blue method. Cells were only used if the viability exceeded 75%.
Cell suspensions were aliquoted (594 μL) into 15 wells of a 24-well plate. An equal volume of KH buffer was aliquoted into 5 wells to serve as controls.
Incubations were initiated by addition of non-radiolabeled naronapride at a final concentration of 10 μM. Diclofenac (100 μM, Sigma-Aldrich, St. Louis, MS) was included and diclofenac hydroxylation and glucuronidation was monitored in all preparations as positive controls to insure that Phase I and Phase II enzymes were active. A separate set of control incubations were performed to determine the stability of the test articles in KH buffer. The plates were incubated at 37 o C with 5% CO 2 . Aliquots (50 µL) were removed from each well at 0, 0.5, 1, 2, 4 and 6 hr after the addition of the test articles. These were added to 100 µL of acetonitrile (with 0.1% formic acid and internal standard chosen to give counts of radioactivity that were distinguishable from background and at least 10-fold higher than expected peak plasma concentrations in vivo. The unbound fraction, corrected for the potential presence of a volume shift, was calculated after the manner of Boudinot & Jusko (1984) .
Plasma protein binding of the naronapride metabolites, ATI-7400 and ATI-7100, was determined by centrifigation/ultrafiltration using non-radiolabeled standards (ARYx Therapeutics, Fremont, CA). Human plasma was spiked with stock solutions of the test articles prepared in DMSO to yield final concentrations of 2.5 µM and 10 µM. The spiked samples were pH-adjusted to 7.4, if necessary, using dilute HCl, incubated at 37°C at 300 rpm (Eppendorf 
RESULTS
Dose
Administration. The mean concentration of radioactivity in the subject dose formulation was 2.01 x 10 7 dpm/g. This value and the specific activity determined in a mock dose analysis (1.76 µCi/mg) were used to determine the amount of dose administered to each subject and in the study calculations. Doses ranged from 115 mg to 116 mg/subject (204 to 205 µCi/subject) and were close to the target dose of 120 mg (200 µCi).
Radio-analysis.
Concentrations of radioactivity in blood and plasma are presented graphically in Figure 2 . The maximum mean concentrations of drug-derived radioactivity in blood and plasma were observed at approximately 1 hour post-dose, with values of 153 and 232 ng-Eq/mL, respectively. Maximum blood radioactivity concentrations in individual subjects were observed from 0.5 to 1 hour postdose and ranged from 81.0 to 319 ng-Eq/mL. Maximum plasma radioactivity concentrations in individual subjects were also observed from 0.5 to 1 hour post-dose and ranged from 124 to 507 ng-Eq/mL. Levels of radioactivity fell below the limit of quantitation in all subjects by 6 and 12 hours post-dose in blood and plasma, respectively.
Mean blood:plasma concentration ratios ranged from 0.570 to 0.683 through 4 hours post-dose.
Excretion and Mass Balance in Urine and
Feces. Approximately 77% of total 14 C was recovered in feces, and 12% was excreted in urine through the last collection interval (Table 1) .
Most of the administered radioactivity was recovered in the first 240 hours postdose (>87%).
Quantifiable levels of radioactivity were found in feces through 552 hours postdose (the last collection interval) and in urine through 528 hours postdose. The overall mean recovery of radioactivity in feces and urine samples was 88.96% over the 552-hour study, with recovery in individual subjects ranging from 81.00% to 91.83%.
The maximum mean concentrations of [ 14 C]-naronapride-derived radioactivity were observed in samples collected from 24 to 48 hours postdose for feces (138,000 ng-Eq/g) and 0
to 2 hours postdose for urine (36,300 ng-Eq/g).
Metabolic
Profiling. The extraction recovery of radioactivity for plasma samples from one subject was 91.8% and 102.8% for 1 hr and 4 hr samples, respectively. The extraction recovery of radioactivity for fecal homogenate samples from a representative subject was 102.5% and 86.3% for 24 hr and 72 hr samples, respectively. The HPLC column recovery was determined to be 101.6% using a urine sample. No correction factors were applied to the plasma and fecal concentrations to account for the recovery.
DMD #37564
20
The metabolic pathways of naronapride are shown schematically in Figure 3 . Seven metabolites (ATI-7400, ATI-7500, ATI-7500 glucuronide, ATI-7100, M4, M9, and M11) were observed in the radiochromatograms of human plasma, urine, and feces and were identified using HPLC/tandem mass spectrometry. Metabolites quinuclidinol and M6 were identified as non-radiolabeled products. M9, a hydroxylation metabolite with the hydroxyl group on the piperidine ring, was observed only in urine in 2 of the 8 subjects and comprised less than 0.06% of the naronapride dose. M11, a glycoside of naronapride, was identified only in fecal samples, and the level was too low to be quantitated. Representative HPLC radiochromatograms for metabolites in plasma, urine and feces are shown in Figure 4 .
The fragmentation pattern of naronapride standard was studied to facilitate the interpretation of the mass spectra of its metabolites. The mass spectrum of naronapride (Supplemental Figure 5) showed a protonated molecular ion at m/z 537; an isotope peak at m/z 539 was also observed due to the presence of a chlorine atom in the molecule. The product ion spectrum of m/z 537 (Supplemental Figure 6) showed a peak at m/z 505 which was formed by a loss of methanol, probably on the piperidine ring. The base peak m/z 305 on the product ion spectrum was formed from m/z 505 by the loss of the amide moiety on the piperidine ring.
Fragments at m/z 184 and m/z 380 are shown in Figure 6 (Supplemental).
Metabolite Identification
Naronapride. The mass spectrum of the peak at about 8.5 minutes (Supplemental Figure Metabolites Observed in Plasma. Naronapride underwent a rapid esterase hydrolysis to ATI-7500 with the stoichiometric loss of quinuclidinol. This hydrolytic step is known to happen in human plasma in vitro (Aryx Therapeutics, unpublished results) and also in human liver microsomes (vide infra). ATI-7500 was then either glucuronidated to phenyl N-glucuronide (M12), or its hexanoic acid side chain underwent two-carbon cleavage to form ATI-7400. The butanoic acid side chain of ATI-7400 underwent a further two-carbon cleavage to form ATI-7100. All of these products were major metabolites of naronapride as indicated by their higher exposure in plasma compared to parent drug and were likely formed in metabolic organs, e.g.., liver and intestine. Due to the fact that ATI-7500 glucuronide co-eluted with parent drug during metabolite profiling (Supplemental Figure 5) , quantitation of this metabolite was not feasible using HPLC coupled with radiomatic detection. Even though ATI-7500 glucuronide appeared to comprise a major portion of the combined peak with naronapride in plasma, it was excreted only in urine and comprised no more than 0.36% of the dose. A very minor amount of
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24 naronapride was found to undergo an N-dealkylation to form M4 with a concomitant loss of the M6 metabolite. Metabolite M4 was below the quantification limit (defined as a 3 to 1 signal to noise on the radiochromatogram) in 4 of the 8 subjects. M6 could not be quantitated due to its lack of radioactivity.
Excretion of Naronapride and its Major Metabolites. Mean percentages of the naronapride dose recovered as urine and fecal radioactivity, naronapride, and its major metabolites are given in Table 1 . Approximately one third of the 14 C dose was recovered as parent drug, mainly in feces. Overall, ATI-7500, ATI-7400 and ATI-7100 accounted for 36.56%, 16.28% and 1.58%, respectively, of the dose. Quinuclidinol would be presumed to be approximately equal to the sum of all the metabolites that had a loss of the quinuclidinol moiety (~ 54% of dose).
Metabolite ATI-7400 was the major radioactive component in the urine of all subjects.
The cumulative urinary recovery for ATI-7400 ranged from 3.84% for subject 4 to 12.75% for subject 5. The cumulative urinary recovery for ATI-7500 ranged from 0.20% for subject 4 to 1.86% for subject 5. The cumulative urinary recovery for naronapride and M12 together ranged from 0.11% for subject 4 to 1.03% for subject 5. The cumulative urinary recovery for all radioactive components ranged from 6.11% for subject 4 to 21.78% for subject 5.
Naronapride and metabolite ATI-7500 were the major radioactive components in the feces of all subjects. The cumulative recovery in feces for naronapride ranged from 4.40% for subject 7 to 63.37% for subject 1. The cumulative recovery in feces for ATI-7500 ranged from 5.84% for subject 1 to 66.61% for subject 3. The cumulative recovery in feces for all radioactive components ranged from 68.92 % for subject 5 to 82.82% for subject 4.
In Vitro Metabolism. The half-life of naronapride (2 µM) exceeded 90 minutes in human liver microsomes (1 mg/mL), and rates of degradation were not dependent on the presence of the NADPH-generating system. Naronapride was hydrolyzed to yield a single acid metabolite, ATI-7500, and the rate of ATI-7500 formation was stoichiometrically related to the rate of naronapride loss. A very small amount of a hydroxylated naronapride metabolite was detected
25 but could not be quantified; its formation was dependent on time and the NADPH-generating system. The site of oxidation on naronapride was identified by LC/MS/MS product ion scan analysis using the fragmentation patterns observed for the parent molecule and its oxidation metabolite. Based on these patterns, the piperidine ring and/or the quinuclidine ring were identified as possible hydroxylation sites.
When incubated with human hepatocytes, naronapride (10 µM) was reduced by half after 194 minutes. The metabolite, ATI-7500, was monitored and its formation was observed to lack the clear stoichiometric relationship with the loss of naronapride that was observed with the microsomal incubations, and small amounts of ATI-7400 resulting from the cleavage of two carbon atoms from the hexanoic acid side chain of ATI-7500 were detected. Approximately 77% of naronapride remained at the end of 6 hr; ATI-7400 comprised 1 to 3% of naronparide metabolized. The formation of ATI-7500 and ATI-7400 together accounted for 41.1% of the metabolism of naronapride (33.6% and 7.5%, respectively). The formation of an oxidative (M+16) metabolite of naronapride was detected in hepatocyte samples. The site of oxidation was identified using the fragmentation pattern observed for naronapride and its oxidation metabolite by product ion scan analysis. Based on the fragmentation patterns, there were two possible sites of oxidation: on the piperidine ring or the quinuclidine ring. The potential for oxidation on the quinuclidine ring was tested by incubating naronapride (10 µM) in human hepatocytes. After a 5 or 6 hr incubation, the samples were split. One set of samples was quenched immediately, and the other set was incubated at 37°C with equine butyrylcholinesterase (BuChE) for 20 min then quenched. The amount of oxidative metabolite remaining when the samples were further incubated with BuChE was significantly less than in the samples that were not exposed to BuChE. In addition, there was a concomitant increase in the amount of ATI-7500 and hydroxy quinuclidinol formed. These results suggest that oxidation of naronapride could take place at a site on the quinuclidine ring of the parent molecule prior to hydrolysis to ATI-7500 and hydroxy quinuclidinol. Naronapride, ATI-7500, ATI-7400, and
26 ATI-7100 were stable in KH buffer during the period of incubation. This result indicated that the degradation of the test articles observed in the hepatocyte suspensions was due to enzymemediated metabolism and not to chemical instability. Diclofenac (control standard) was metabolized rapidly. The amount of diclofenac remaining at the end of 6 hr incubation was approximately 9%. The Phase I metabolite (4-hydroxy diclofenac) and Phase II metabolites (diclofenac glucuronide and hydroxy diclofenac glucuronide) were formed and indicated that Phase I and Phase II enzymes were active in the hepatocyte system.
A significant portion of naronapride metabolized in hepatocytes (>50%) was not accounted for by metabolites for which chemical standards were available. A more detailed description of these in vitro observations will be published elsewhere.
In Vitro Plasma Protein Binding. Plasma protein binding of naronapride and its principal metabolites, ATI-7500, ATI-7400, and ATI-7100, are given in Table 2 The absolute oral bioavailability of naronapride is not known, however the small amount of the dose recovered in the urine (12%), the relatively low amounts of naronapride in plasma, and the large amounts of unchanged drug present in the feces (32%), are consistent with it being low.
The oral bioavailability of naronapride in rats and dogs is approximately 25% (ARYx Therapeutics, unpublished results) and supports this speculation. The presence of naronapride in feces has important therapeutic implications, as accumulating evidence indicates that the enterokinetic actions of 5-HT 4 agonists are mediated by the facilitation of synaptic transmission in the gut myenteric plexus by blood-borne drug and by local interactions with targets in the intestinal mucosal epithelium 1998; Jin et al., 1999; Balemba & Mawe, 2009) .
Accordingly, the current findings suggest the prokinetic actions of naronapride could result from both its systemic uptake and local interactions with the colonic epithelium. suggest that once-a-day dosing may also be effective.
Naronapride was specifically designed to undergo metabolism by tissue and circulating esterases in order to minimize cytochrome P450-mediated drug-drug interactions. Results of this study confirmed that, as designed, naronapride is principally subject to rapid hydrolysis. In all, seven major naronapride metabolites were identified in plasma (Figure 3 ): ATI-7500, a hydrolysis product is formed by cleavage of the ester bond; ATI-7400, an oxidation product of ATI-7500; ATI-7100, an oxidation metabolite of ATI-7400; a glucuronide of ATI-7500 (M12); an N-dealkylation product of naronapride (M4); a hydroxylation product of naronapride (M9); and a glycoside of naronapride (M11). The detection of M11 in feces was unusual given that the mass spectrometric interpretation indicated that it was a glycoside conjugate of naronapride. The molecular ion of M11 was 162 Da more than that of naronapride and the product ion spectrum of m/z 699 showed peak at m/z 537, which was formed by loss of hexose (glucose or galactose)
moiety. In addition, N-glucosides have been noted in the literature as conjugates present in urine and bile from other mammalian species and this metabolite represented only a very minor pathway for elimination (Tang, 1990; Tang et al., 2003; Nakazawa et al., 2006) . Two metabolites without 14 C label were 3-quinuclidinol, an ester hydrolysis product of naronapride
29 and an N-dealkylation product of naronapride with dealkylation at piperidine nitrogen (M6).
ATI-7500, ATI-7400, and ATI-7100 together accounted for most of the radioactivity in plasma (70%). O-dealkylation could lead to the loss of label, but because most of the dose was recovered in the plasma, urine, and feces, the amount of metabolite formed via this pathway must be negligible. In vitro binding and cell-based functional assays showed that ATI-7500, ATI-7400 and ATI-7100 are weak partial agonists of human 5-HT 4(b) receptor and have no meaningful affinities for dopamine D 2 receptors. Like naronapride, ATI-7500, ATI-7400, ATI-7100 have negligible affinity for cardiac I Kr channels and were essentially devoid of electrophysiological effects in guinea pig myocardium. Broad receptor profiling and affinity data have been collected for the ATI-7500 metabolite only. In wide-spectrum competitive radioligand binding assays, ATI-7500 had no relevant affinity for a diverse array of more than 64 molecular targets including receptors, ion channels, and transporters.
Naronapride hydrolysis to ATI-7500 by esterases appears to be a primary route of naronapride metabolism in hepatic microsomes. The rate of naronapride degradation by human liver microsomes was not dependent on the presence of NADPH indicating that naronapride loss was primarily by esterase-mediated hydrolysis and not oxidative metabolism in this subcellular fraction. A small, though not quantified, amount of a hydroxylated metabolite was detected after incubation of naronapride with microsomes and its formation was time dependent
and required the addition of the NADPH-generating system. The formation of this metabolite could be due to CYP450-mediated oxidative ester hydrolysis of naronapride, however further work would be required to confirm this hypothesis. Thus, although some CYP450 involvement in naronapride metabolism was found in human liver microsomes, collectively these data suggest that naronapride is a poor substrate for CYP450.
In contrast to the results of the metabolism of naronapride with human liver microsomal preparations, incubation with human hepatocytes led to the formation of metabolites other than ATI-7500 (e.g., ATI-7500 formation accounted for only 34% of naronapride metabolism). One of
30 these, ATI-7400 (an oxidation product resulting from a two carbon cleavage of the hexanoic acid side chain of ATI-7500) was possibly a product of β-oxidation, a process that occurs in mitochondria and peroxisomes and is normally associated with fatty acid metabolism (Suga, 2003) . Liver microsomes are a post-mitochondrial fraction, and this probably accounts for the lack of ATI-7400 or ATI-7100 formed in incubations using this preparation.
The primary route of elimination of recovered radioactivity was via fecal excretion (77%), and naronapride was mainly eliminated through hydrolysis reactions and excretion of unchanged drug. Hydrolytic cleavage of the quinuclidinol moiety accounted for the elimination of 36.56% of the dose (0.93% in urine and 35.63% in feces). ATI-7500 was subject to sequential 2-carbon cleavage of its aliphatic acid side chain, and peak concentrations for ATI-7400 and ATI-7100 were reached within one hour of the naronapride t max , indicating that the process was fairly rapid. Quinuclidinol plasma concentrations reached peak levels within 1 hour after dosing, and the overall AUC was approximately 4-times that of ATI-7500, ATI-7400, and ATI-7100 combined. Oxidation of the quinuclidine moiety was detected in hepatocytes and findings suggested this occurred prior to naronapride hydrolysis to ATI-7500. In another study, quinuclidinol, at concentrations to 10 µM, was stable over a 90 minute incubation period in in vitro incubations with mouse, rat, and human liver S9 fractions at 37°C, i.e., neither hydroxylated derivatives of quinuclidinol nor other potential biotransformation products were detected (Procter and Gamble, unpublished findings). A' e (%) is the mean of the percentage of dose excreted.
%CV m is the coefficient of variation of the mean.
a All urine and feces was collected and analyzed b Percentage of recovery of naronapride and ATI-7500 glucuronide combined. Glucuronidated ATI-7500
was not independently quantified.
39 c CL r is the renal clearance, determined as the quotient of the cumulative amount excreted in urine from time 0 to t last divided by AUC(t last ).
d MR is the metabolite/parent ratio, based on AUC, where the AUC of the metabolite is truncated to the t last of the naronapride in plasma.
e 14 C pharmacokinetic parameter estimates based on radioactivity data obtained in plasma
